Form 4: Corcept Therapeutics Director Gregg H. Alton Reports Stock Option Grant

Director Gregg H. Alton of Corcept Therapeutics reported the acquisition of stock options on May 17, 2024.

Summary

• Gregg H. Alton, a director of Corcept Therapeutics, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 17, 2024.
• Alton acquired stock options to purchase 30,000 shares of Corcept Therapeutics common stock at an exercise price of $28.09.
• The options vest ratably in equal monthly installments over one year, starting May 17, 2024, and expire on May 16, 2034.
• Following the reported transaction, Alton directly owns derivative securities for 30,000 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company for at least one year.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Option grants are a common form of executive compensation in the pharmaceutical industry.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates